Thermo Fisher Scientific will develop manufacturing processes for cancer cell therapies in collaboration with Lyell Immunopharma. The deal – financial terms of which were not provided – will focus on improving the “fitness” of T cells from which cell therapies are produced according to the firms. A T-cells metabolic “fitness” describes the likelihood it can be turned into a cell therapy. Cell therapies need to be fit because of the high metabolic demands of tumor cells can negatively impact their…

AGC Biologics has acquired Molecular Medicine (MolMed), increasing its presence in the CDMO space and adding a pipeline of cell and gene therapy candidates. In March, contract development and manufacturing organization (CDMO) AGC Biologics launched a voluntary tender offer to acquire Italian cell and gene therapy developer and manufacturer MolMed for €240 million ($284 million). Today the deal has been completed, bulking out AGC’s biopharma offering. On the services side, AGC adds two GMP sites in Milan and Bresso, both…